Hepion Pharmaceuticals Inc. buy melinda
Start price
31.08.18
/
50%
€872.59
Target price
23.01.19
€1,767.9
Performance (%)
-51.85%
End price
23.01.19
€420.13
Summary
This prediction ended on 23.01.19 with a price of €420.13. The BUY prediction by melinda for Hepion Pharmaceuticals Inc. performed very badly with a performance of -51.85%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Hepion Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -0.922% | -1.078% | 12.165% | 16.796% |
| iShares Nasdaq 100 | 0.371% | -0.556% | 38.622% | 49.370% |
| iShares Nikkei 225® | 2.224% | -2.825% | 19.015% | 4.643% |
| iShares S&P 500 | -0.026% | -0.788% | 28.485% | 42.479% |
Comments by melinda for this prediction
In the thread Hepion Pharmaceuticals Inc. diskutieren
SecteurRecherche biotechnologique et médicale
Operates as a development stage company
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline.
The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus.
ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.
ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline.
The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus.
ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.
Nombre d'employés : 21 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€27.40
25.11.20
25.11.20
€40.00
25.11.21
25.11.21
-16.20%
26.11.21
26.11.21
Hepion Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€44.00
23.03.20
23.03.20
€100.00
04.11.21
04.11.21
-37.73%
25.11.20
25.11.20
Hepion Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€8,950.7
26.04.17
26.04.17
€14,143
26.10.17
26.10.17
-37.61%
26.10.17
26.10.17
Hepion Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€10,405
10.07.16
10.07.16
€12,123
17.08.16
17.08.16
17.09%
17.08.16
17.08.16